Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Elite Clinical Trials LLLP

Neither a doctor nor a teaching hospital

Research payments

$5,523,881

883 payments

Through program year 2025, Elite Clinical Trials LLLP is reported as receiving $5,523,881 in research payments, across 883 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $801,877 48
2024 Research $839,219 25
2023 Research $954,553 60
2022 Research $1,149,852 450
2021 Research $628,364 225
2020 Research $436,681 43
2019 Research $713,335 32

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $4,115,162 101 payments
  2. Supernus Pharmaceuticals, Inc. $425,386 28 payments
  3. Novo Nordisk AS $332,385 591 payments
  4. Pfizer Inc. $284,036 50 payments
  5. Regeneron Pharmaceuticals, Inc. $193,179 38 payments
  6. GlaxoSmithKline, LLC. $169,240 74 payments
  7. Eli Lilly Export S.A. Puerto Rico Branch $4,494 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight With Weight Related Comorbidities (Attain-1) $549,927 4 payments
  2. A Phase 2 Study of Once-Daily Ly3502970 Compared With Placebo in Participants Who Have Obesity Or Are Overweight With Weight-Related Comorbidities $461,811 3 payments
  3. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $314,997 8 payments
  4. A Phase IV, Open-Label, Flexible-Dose Safety Trial Evaluating Spn-812 Administered With Psychostimulants in Children and Adolescents (6 to 17 Years of Age) With Disorder (Adhd) Attention-Deficit/Hyperactivity $310,180 12 payments
  5. A Study of Ly3209590 in Participants With Type 2 Diabetes Mellitus $277,847 3 payments
  6. A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight With Weight Related Comorbidities (Attain-1) $249,665 2 payments
  7. A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial $242,280 4 payments
  8. A Phase 2, Parallel, Comparator Controlled Trial to Evaluate the Safety and Efficacy of Ly3209590 in Insulin Naive Patients With Type 2 Diabetes Mellitus $197,204 3 payments
  9. A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity $193,179 38 payments
  10. A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $192,451 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record